TY - JOUR
TI - Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal
Aortic Aneurysms: a Systematic Review
AU - Mohamed, Naser
AU - Galyfos, George
AU - Anastasiadou, Christiana and
AU - Sachmpatzidis, Ioannis
AU - Kikiras, Konstantinos
AU - Papapetrou,
AU - Anastasios
AU - Giannakakis, Sotirios
AU - Kastrisios, Georgios and
AU - Papacharalampous, Gerasimos
AU - Geroulakos, Georgios
AU - Maltezos,
AU - Chrisostomos
JO - Annals of Vascular Surgery
PY - 2020
VL - 63
TODO - null
SP - 399-408
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - 0890-5096
TODO - 10.1016/j.avsg.2019.09.016
TODO - null
TODO - Background: This review aims to collect all available data on early and
late outcomes in patients undergoing fenestrated endovascular aortic
aneurysm repair (F-EVAR) for pararenal or juxtarenal abdominal aortic
aneurysms (AAAs).
Methods: The Pubmed, Embase, Scopus and Cochrane Library databases were
systematically searched to identify eligible studies. Studies reporting
at least early mortality after F-EVAR in patients with pararenal or
juxtarenal AAA were included. Thirty-day outcomes were defined as early,
and outcomes reported after 30 days postoperatively were defined as
late. Basic characteristics of all studies and demographics of patients
were reported.
Results: Overall, 30 studies (17 retrospective and 13 prospective)
including 23,385 patients in total were included. Out of 23,385
patients, a total of 2,271 patients were treated with F-EVAR for
pararenal/juxtarenal AAA. Overall, 4,216 target vessels were to be
treated (data from 24 studies). Pooled early mortality reached 2.55%
(ranging from 0% to 6.74%), with a pooled technical success of 96.8%
(ranging from 82.8% to 100%). Regarding late outcomes, pooled allcause
mortality reached 17% (ranging from 0% to 50%), 1-year primary
patency was 94.6% (ranging from 91.8% to 97.1%) and reintervention
rate was 10.4% (ranging from 0% to 57.4%). Mean/median follow-up
ranged from 3 to 60 months.
Conclusions: Early outcomes indicate that F-EVAR is a safe and efficient
treatment for patients with pararenal/juxtarenal AAAs. Although
long-term outcomes are acceptable, late-intervention rate remains high.
ER -